Minorities Need to Be Included in Clinical Trials

A 39-year old patient of mine was watching the New England Patriots game when he noticed blood on his shirt coming from his left nipple. Another 42-year old patient found a lump in his breast and changes in his nipple that didn't go away. Men get breast cancer too, and they're spreading the word. Male Breast Cancer awareness is taking off, with celebrities like Samuel Jackson and Mark Ruffalo tweeting pictures of their nipples last week to raise awareness as part of the #InTheNipOfTime campaign, and 24 states in the union officially designating the third week in October to be "Male Breast Cancer Awareness Week". But awareness is not enough. Most breast cancer treatments are based on clinical trials done primarily in women, who comprise 99% of the breast cancer population; the results are then extrapolated to men. But is this appropriate? Just as we now realize that heart disease may be a different phenomenon in women as it is in men and lament the fact that few women participated in the trials that defined management of cardiac conditions, we tend to treat conditions based on data derived from patients who participate in clinical trials, often to the detriment of minorities who either were not afforded the opportunity or chose not to participate. Part of the blame for this rests with those of us who are clinical investigators. How many studies are focused solely on male breast cancer? Or even worse, how many trials of breast cancer treatments exclude men altogether?...
Source: Science - The Huffington Post - Category: Science Source Type: news

Related Links:

Publication date: Available online 23 March 2019Source: The Annals of Thoracic SurgeryAuthor(s): Donglai Chen, Yiming Mao, Junmiao Wen, Yunlang She, Erjia Zhu, Feng Zhu, Yongsheng Zhang, Min Fan, Chang Chen, Yongbing ChenAbstractBackgroundA series of studies have assessed the clinicopathological features and prognostic impact of STAS in non-small cell lung cancer (NSCLC) bringing conflicting findings so far. We performed a systematic review and meta-analysis to synthesize the available evidence regarding to the prognostic value of STAS in NSCLCs.MethodsStudies were identified by searching databases including PubMed, EMBASE...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
This study represents a pooled analysis from the control arms of two clinical trials (NCT00290966; NCT00678535). Both control arms evaluated fluoropyrimidine/cisplatin combination in the first line treatment of advanced gastric cancer. Univariate and multivariate Cox regression analyses were performed to assess factors affecting overall and progression-free survival. Factors with P
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
Publication date: Available online 24 March 2019Source: Journal of Molecular LiquidsAuthor(s): Achal Mukhija, Nand KishoreAbstractBiocompatibility and ease of surface modification make gold nanoclusters potential to be used in nanomedicine and revolutionizing cancer therapy. Low solubility and bioavailability of drug limits the use of conventional drug administrative methods and hence the need for drug delivery vehicles arises. Different drug delivery vehicles have been used in the past but usually, the information is limited to qualitative in nature. Here, we have reported quantitative insights into interaction of human s...
Source: Journal of Molecular Liquids - Category: Molecular Biology Source Type: research
CONCLUSIONS: In the presence of progressive dyspnea, cough, and lesions comparable to interstitial lung disease, diagnosis of PLC should be considered. Pulmonary lymphangitis carcinomatosis can be the first manifestation of primary occult neoplasm and may occur at any age. Adenocarcinoma, especially primary lung, breast, and gastric cancers is the most common cancer coexisting with PLC. PMID: 30900501 [PubMed - as supplied by publisher]
Source: Postgraduate Medicine - Category: Internal Medicine Tags: Postgrad Med Source Type: research
Publication date: Available online 23 March 2019Source: Chemico-Biological InteractionsAuthor(s): Yehoshua Socol, Yair Y. Shaki, Alexander Vaiserman
Source: Chemico Biological Interactions - Category: Biochemistry Source Type: research
Publication date: 23 March 2019Source: New Scientist, Volume 241, Issue 3222Author(s): Michael Le Page
Source: New Scientist - Category: Science Source Type: research
PURPOSE: Multiple myeloma is a chronic, uncurable hematological cancer with the involvement of multiple organ systems. As a disease affecting older patients, the treatment of multiple myeloma should be based on individual patient characteristics. Polypharm...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
Authors: Wang X, Wang H, Xu B, Jiang D, Huang S, Yu H, Wu Z, Wu Q Abstract DOT1-like protein (Dot1L) is the sole methyltransferase for methylation of lysine 79 in histone H3. Dot1L-dependent H3K79 methylation is involved in many biological processes, including telomeric silencing, cell cycle regulation, transcriptional activation and DNA repair. Genome-wide sequencing studies have revealed recurrent deletion and mutations of Dot1L gene in many types of human malignancies including ovarian cancer, however the role of Dot1L in ovarian cancer are largely unknown. To demonstrate the role of Dot1L in ovarian cancer, the...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
CONCLUSION: SNHG6 may exert oncogenic function in ESCC and may be a potential diagnostic marker for this cancer. PMID: 30899408 [PubMed]
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
It is now 2016, and Americans hope for a brighter, healthier new year. Are Americans healthier today than they were last year or the year before? Will there be fewer people diagnosed with cancer? According to the American Cancer Society, it is projected that in 2016 there will be 1,685,210 new cancer cases and 595,690 deaths due to cancer. This is an increase over previous years. While it is true that the death rate for several cancers has decreased (due mostly to better screening and earlier diagnosis), it is also true that several cancers are on the rise, including cancers of the thyroid, liver, pancreas, kidney, small i...
Source: Healthy Living - The Huffington Post - Category: Consumer Health News Source Type: news
More News: African Health | Biology | Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Cardiology | Clinical Trials | Funding | Health | Heart | Heart Disease | Male Breast Cancer | National Institutes of Health (NIH) | Science | Study | Websites | Women